Pharmacology of Antifungal Drugs

Introduction/Overview

The management of fungal infections represents a significant and growing challenge in clinical medicine. The increasing prevalence of invasive mycoses is closely associated with the expansion of immunocompromised patient populations, including those undergoing chemotherapy, organ transplantation, or living with HIV/AIDS, as well as the widespread use of broad-spectrum antibiotics and invasive medical devices. Fungal pathogens exhibit eukaryotic cellular organization, which presents a fundamental therapeutic challenge: identifying biochemical targets that are unique to fungal cells while sparing human host cells. This narrow therapeutic window often complicates treatment and contributes to the toxicity profiles of many antifungal agents. The field of antifungal pharmacology has evolved considerably, moving from a reliance on a few toxic compounds to a broader arsenal of agents with varying spectra of activity, mechanisms of action, and pharmacokinetic properties. A thorough understanding of these drugs is essential for optimizing therapeutic outcomes and minimizing harm.

Learning Objectives

• Classify major antifungal drug families based on their chemical structure and primary mechanism of action.
• Explain the molecular and cellular pharmacodynamics of polyenes, azoles, echinocandins, and other antifungal classes.
• Analyze the pharmacokinetic profiles, including absorption, distribution, metabolism, and excretion, of systemic antifungal agents.
• Correlate the spectrum of activity of different antifungals with their appropriate clinical applications for superficial and systemic mycoses.
• Evaluate the major adverse effect profiles and drug interaction potentials to inform safe prescribing practices in diverse patient populations.

Classification

Antifungal drugs are systematically categorized according to their chemical structure and site of action. This classification provides a framework for understanding their spectra of activity, resistance patterns, and clinical utility.

Chemical and Mechanistic Classification

The primary classes of antifungal agents used in systemic therapy include:

• Polyene Macrolides: Characterized by a large macrolide ring with both hydrophilic and lipophilic regions. The prototype is amphotericin B. Nystatin is a related polyene used exclusively for topical or mucosal applications due to systemic toxicity.
• Azole Antifungals: Synthetic compounds containing a five-membered azole ring. This large class is subdivided into:
  • Imidazoles (e.g., ketoconazole, miconazole, clotrimazole).
  • Triazoles (e.g., fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole). Triazoles generally possess improved specificity and safety profiles compared to imidazoles.
• Echinocandins: Semisynthetic lipopeptides that inhibit fungal cell wall synthesis. Examples include caspofungin, micafungin, and anidulafungin.
• Antimetabolites:
  • Flucytosine (5-FC): A fluorinated pyrimidine analog.
• Allylamines: Synthetic agents such as terbinafine and naftifine, which inhibit squalene epoxidase.
• Other Agents: This category includes griseofulvin (an older oral agent for dermatophytoses) and various topical agents like ciclopirox and tolnaftate.

An alternative classification is based on the site of action: drugs affecting the cell membrane (polyenes, azoles, allylamines), the cell wall (echinocandins), or nucleic acid synthesis (flucytosine).

Mechanism of Action

The efficacy of antifungal drugs hinges on their ability to selectively disrupt essential fungal cellular processes. The mechanisms are distinct for each major class.

Polyenes: Membrane Disruption

Amphotericin B and other polyenes exert their fungicidal effect by binding irreversibly to ergosterol, the principal sterol component of the fungal cell membrane. The amphotericin B molecule is amphipathic, with a hydrophobic polyene hydrocarbon chain and a hydrophilic polyhydroxyl region. This binding forms transmembrane pores or channels, consisting of an annulus of eight amphotericin B molecules linked hydrophobically to ergosterol. The hydrophilic core of these pores allows for the unregulated leakage of intracellular ions (particularly potassium) and small molecules, leading to disruption of electrochemical gradients, metabolic dysfunction, and ultimately cell death. A contributory mechanism involves the induction of oxidative damage to fungal cells. Selective toxicity is theoretically achieved because mammalian cell membranes contain cholesterol rather than ergosterol; however, amphotericin B does exhibit a lower affinity for cholesterol, which accounts for its significant human toxicity.

Azoles: Inhibition of Ergosterol Biosynthesis

Azole antifungals are fungistatic agents that inhibit the synthesis of ergosterol. Their primary target is lanosterol 14α-demethylase, a cytochrome P450-dependent enzyme (encoded by the ERG11 gene in yeast). This enzyme catalyzes the removal of a methyl group from lanosterol, a critical step in the conversion of lanosterol to ergosterol. Azoles act as competitive inhibitors by binding to the heme iron atom in the active site of the cytochrome P450 enzyme via their unsubstituted nitrogen atom. Inhibition leads to the accumulation of toxic methylated sterol precursors (e.g., 14α-methylergosta-8,24(28)-dien-3β,6α-diol) and depletion of ergosterol. The resultant fungal cell membrane becomes structurally unstable, leaky, and dysfunctional, impairing the activity of membrane-associated enzymes. The greater specificity of triazoles for fungal cytochrome P450 enzymes, compared to imidazoles, underlies their improved safety profile.

Echinocandins: Inhibition of Cell Wall Synthesis

Echinocandins are fungicidal against many Candida species and fungistatic against Aspergillus. They non-competitively inhibit the enzyme β-(1,3)-D-glucan synthase, a complex located in the fungal cell membrane. This enzyme is responsible for the synthesis of β-(1,3)-D-glucan, a vital polysaccharide fibril that provides structural integrity and rigidity to the fungal cell wall. Inhibition leads to a reduction in glucan content, weakening the cell wall. This results in osmotic instability, aberrant cell growth, and ultimately cell lysis. Since mammalian cells lack a cell wall and the β-(1,3)-D-glucan synthase enzyme, this mechanism offers a high degree of selective toxicity.

Flucytosine: Inhibition of Nucleic Acid Synthesis

Flucytosine (5-fluorocytosine) is a prodrug that requires fungal-specific cytosine deaminase for activation. Upon uptake into fungal cells via a cytosine permease, it is deaminated to 5-fluorouracil (5-FU). 5-FU is then converted to two active metabolites: 5-fluorodeoxyuridine monophosphate (5-FdUMP) and 5-fluorouridine triphosphate (5-FUTP). 5-FdUMP is a potent inhibitor of thymidylate synthase, disrupting DNA synthesis. 5-FUTP is incorporated into fungal RNA, disrupting protein synthesis. The requirement for fungal-specific enzymes for activation provides selectivity, but resistance emerges rapidly if used as monotherapy. It is typically used in combination with other antifungals, most commonly amphotericin B, for synergistic effect.

Allylamines and Thiocarbamates

Allylamines (terbinafine, naftifine) and the related thiocarbamate tolnaftate inhibit the enzyme squalene epoxidase. This enzyme catalyzes the conversion of squalene to squalene 2,3-epoxide, an early step in ergosterol biosynthesis. Inhibition leads to squalene accumulation, which is toxic to the fungal cell, and ergosterol depletion. Terbinafine is fungicidal against dermatophytes.

Pharmacokinetics

The pharmacokinetic properties of antifungal drugs vary widely between classes and individual agents, profoundly influencing their route of administration, dosing regimens, and penetration into infection sites.

Absorption and Administration

Oral bioavailability differs significantly among systemic antifungals. Fluconazole exhibits high oral bioavailability (>90%), unaffected by gastric pH or food. Itraconazole capsules require an acidic gastric environment for optimal absorption and should be taken with food or an acidic beverage; the oral solution, formulated with cyclodextrin, has better bioavailability on an empty stomach. Voriconazole also has high oral bioavailability (>95%), while posaconazole delayed-release tablets show improved absorption compared to the oral suspension. Isavuconazole is available as a prodrug, isavuconazonium sulfate, with high bioavailability. Ketoconazole absorption is erratic and highly dependent on gastric acidity. Echinocandins and amphotericin B deoxycholate and lipid formulations are not absorbed orally and must be administered intravenously. Flucytosine is well-absorbed orally.

Distribution

Distribution characteristics are crucial for treating infections in sequestered sites. Fluconazole has low protein binding (~12%) and distributes widely into total body water, including cerebrospinal fluid (CSF), where concentrations may reach 50-90% of plasma levels. Voriconazole also penetrates the CSF well. In contrast, itraconazole, posaconazole, and isavuconazole are highly protein-bound (>98%) and achieve negligible CSF concentrations, though they distribute extensively into tissues. Amphotericin B binds extensively to proteins and distributes predominantly to the liver, spleen, and lungs, with poor penetration into the CSF, vitreous humor, and amniotic fluid. Lipid formulations are taken up by the reticuloendothelial system, altering their distribution. Echinocandins are highly protein-bound and distribute well into most tissues but have limited CSF penetration.

Metabolism and Excretion

Metabolic pathways are a major source of drug interactions, particularly for the azoles. The triazoles are primarily metabolized by hepatic cytochrome P450 enzymes. Fluconazole is a moderate inhibitor of CYP2C9 and CYP3A4. Itraconazole, voriconazole, posaconazole, and isavuconazole are both substrates and potent inhibitors of CYP3A4, with voriconazole also affecting CYP2C19. Their metabolism is saturable, leading to non-linear pharmacokinetics for voriconazole and itraconazole. Amphotericin B is not metabolized to a significant extent and is slowly excreted via both renal and biliary routes over weeks to months. Echinocandins undergo hepatic metabolism via hydrolysis and N-acetylation, followed by biliary and fecal excretion. Flucytosine is minimally metabolized and is primarily excreted unchanged in the urine, necessitating dose adjustment in renal impairment.

Half-life and Dosing Considerations

Elimination half-lives dictate dosing frequency. Fluconazole has a long half-life (20-30 hours), permitting once-daily dosing. Itraconazole half-life is dose-dependent but generally allows for once or twice-daily dosing. Voriconazole exhibits non-linear kinetics with a half-life of approximately 6 hours, requiring twice-daily dosing or a continuous IV infusion. Posaconazole and isavuconazole have half-lives suitable for once-daily maintenance dosing. Amphotericin B deoxycholate is typically administered once daily, while lipid formulations may also be given once daily. The echinocandins have half-lives ranging from 10-15 hours (caspofungin, micafungin) to 24-48 hours (anidulafungin), supporting once-daily administration. The short half-life of flucytosine (3-6 hours) requires multiple daily doses, usually given every 6 hours.

Therapeutic Uses/Clinical Applications

The selection of an antifungal agent is guided by the suspected or proven pathogen, the site and severity of infection, host immune status, and local resistance patterns.

Treatment of Specific Fungal Pathogens

Candidiasis: For uncomplicated oropharyngeal or esophageal candidiasis, fluconazole is first-line. For invasive candidiasis, echinocandins (caspofungin, micafungin, anidulafungin) are recommended as first-line therapy for most patients, particularly the critically ill or those with recent azole exposure. Fluconazole remains an option for stable patients without prior azole exposure and with fluconazole-susceptible isolates. Amphotericin B formulations are alternatives, often reserved for resistant infections or when other agents are contraindicated. Candida auris infections frequently require combination therapy based on susceptibility testing.

Aspergillosis: Voriconazole is the primary therapy for invasive aspergillosis. Isavuconazole is a non-inferior alternative and may be better tolerated. Liposomal amphotericin B is a standard second-line agent. Posaconazole and itraconazole are used for prophylaxis in high-risk patients and as salvage therapy.

Cryptococcosis: Induction therapy for cryptococcal meningitis typically involves amphotericin B (usually liposomal) combined with flucytosine for at least two weeks, followed by consolidation and maintenance therapy with fluconazole.

Mucormycosis: Lipid formulation amphotericin B (particularly liposomal) is the first-line therapy, often combined with surgical debridement. Posaconazole or isavuconazole are used as step-down oral therapy or salvage treatment.

Endemic Mycoses: Histoplasmosis, blastomycosis, and coccidioidomycosis are often treated initially with liposomal amphotericin B for severe disease, followed by long-term azole therapy (itraconazole is preferred for histoplasmosis and blastomycosis; fluconazole or itraconazole for coccidioidomycosis).

Dermatophytoses: Extensive cutaneous infections or onychomycosis may be treated orally with terbinafine (first-line for nail infections) or itraconazole. Fluconazole is also effective for some dermatophyte infections.

Prophylaxis

Antifungal prophylaxis is indicated in specific high-risk populations, such as hematopoietic stem cell transplant recipients and patients with prolonged neutropenia. Posaconazole and voriconazole are commonly used for prophylaxis against invasive aspergillosis. Fluconazole is effective for prophylaxis against candidiasis in certain transplant and ICU settings.

Adverse Effects

The adverse effect profiles of antifungal agents are often class-specific and can be dose-limiting.

Polyene Toxicity

Amphotericin B deoxycholate is associated with significant, often immediate, adverse effects. Infusion-related reactions, including fever, chills, rigors, hypotension, tachycardia, and nausea, are common and are thought to be mediated by prostaglandin release and cytokine induction. Premedication with antipyretics, antihistamines, or corticosteroids is standard. Nephrotoxicity is the major dose-limiting adverse effect, manifesting as decreased glomerular filtration rate, renal tubular acidosis, hypokalemia, and hypomagnesemia due to renal tubular injury. Vigorous hydration and sodium loading may mitigate this risk. Lipid formulations (liposomal amphotericin B, amphotericin B lipid complex) significantly reduce the incidence of nephrotoxicity and infusion reactions but are more costly.

Azole Toxicity

Adverse effects vary among azoles. Hepatotoxicity, ranging from asymptomatic elevation of liver enzymes to fulminant hepatic failure, is a class effect, with ketoconazole carrying the highest risk and a black box warning. Endocrine effects, particularly with ketoconazole, include inhibition of adrenal and gonadal steroid synthesis, leading to gynecomastia, menstrual irregularities, and adrenal insufficiency. Visual disturbances (photopsia, blurred vision) are unique to voriconazole and are usually reversible. QTc interval prolongation is a risk with several azoles, notably voriconazole and fluconazole at high doses, potentially leading to torsades de pointes. Voriconazole is also associated with periostitis, skeletal pain, and phototoxic skin reactions. Itraconazole can cause congestive heart failure and peripheral edema. Posaconazole and isavuconazole are generally better tolerated, with gastrointestinal upset being common.

Echinocandin Toxicity

Echinocandins are generally well-tolerated. The most common adverse effects include histamine-mediated infusion reactions (flushing, rash, pruritus, hypotension) if infused too rapidly, and mild gastrointestinal symptoms. Transient elevations in liver enzymes may occur. Caspofungin has been associated with rare cases of clinically significant hepatitis.

Flucytosine Toxicity

The major toxicities are bone marrow suppression (leukopenia, thrombocytopenia) and gastrointestinal toxicity (nausea, vomiting, diarrhea). These effects are dose-dependent and more common when serum levels exceed 100 μg/mL, emphasizing the need for therapeutic drug monitoring. Hepatotoxicity may also occur.

Drug Interactions

Drug interactions are a paramount concern, especially with azole antifungals, due to their potent effects on hepatic cytochrome P450 enzymes.

Major Drug-Drug Interactions

Azoles as Inhibitors: Itraconazole, voriconazole, posaconazole, and ketoconazole are strong inhibitors of CYP3A4. They can significantly increase plasma concentrations of co-administered drugs metabolized by this pathway, potentially leading to toxicity. Key interactions include:

• Statins: Increased risk of myopathy/rhabdomyolysis with simvastatin, lovastatin, and to a lesser extent, atorvastatin.
• Calcium Channel Blockers: Potentiated hypotensive effects.
• Immunosuppressants: Dramatically increased levels of cyclosporine, tacrolimus, and sirolimus, necessitating close monitoring and dose reduction.
• Benzodiazepines: Enhanced sedative effects with midazolam and triazolam (contraindicated).
• Others: Increased levels of vinca alkaloids, ergot alkaloids, quinidine, pimozide, and certain antiretrovirals (e.g., protease inhibitors, maraviroc).

Azoles as Substrates: Inducers of CYP450 enzymes (e.g., rifampin, rifabutin, phenytoin, carbamazepine, long-acting barbiturates, St. John’s wort) can markedly reduce azole concentrations, leading to therapeutic failure. Rifabutin levels are increased by azoles, raising the risk of uveitis.

Amphotericin B Interactions: Concurrent use with other nephrotoxic agents (aminoglycosides, cyclosporine, cisplatin, furosemide) potentiates renal damage. Hypokalemia induced by amphotericin B can potentiate the effects of digoxin and neuromuscular blocking agents.

Flucytosine Interactions: Cytotoxic agents enhance its bone marrow toxicity. Amphotericin B may increase flucytosine toxicity by impairing renal excretion.

Contraindications

Absolute contraindications are often specific to individual drugs. Ketoconazole is contraindicated in acute or chronic liver disease and with drugs that prolong the QT interval or are highly dependent on CYP3A4 clearance. Voriconazole is contraindicated with high-dose ritonavir, rifampin, rifabutin, carbamazepine, long-acting barbiturates, ergot alkaloids, and St. John’s wort. Terbinafine is contraindicated in individuals with chronic or active liver disease. Amphotericin B is contraindicated in patients with severe hypersensitivity to the drug itself, though test doses are often administered.

Special Considerations

The use of antifungal agents requires careful adjustment in specific patient populations due to altered pharmacokinetics, increased susceptibility to toxicity, or teratogenic potential.

Pregnancy and Lactation

Most systemic antifungal agents carry risks in pregnancy. Azoles are generally teratogenic, especially with first-trimester exposure. High-dose fluconazole (≥400 mg/day) is associated with a distinct pattern of birth defects (craniofacial, skeletal, cardiac). Lower doses for vaginal candidiasis appear to carry minimal risk. Itraconazole and voriconazole are also teratogenic and contraindicated. Amphotericin B is often considered the drug of choice for life-threatening systemic mycoses in pregnancy due to its lack of teratogenicity, despite its maternal toxicity. Flucytosine is teratogenic in animals and should be avoided. Echinocandins have limited data; use is reserved for situations where benefits outweigh risks. For lactation, most systemic antifungals are excreted in breast milk, and their use typically necessitates a decision to discontinue breastfeeding.

Pediatric Considerations

Dosing is typically weight-based or body surface area-based. Voriconazole metabolism is more rapid in children than adults, often requiring higher mg/kg doses to achieve therapeutic levels. The IV formulation contains sulfobutyl ether β-cyclodextrin sodium, which accumulates in renal impairment; its use in pediatric patients with moderate-to-severe renal dysfunction requires caution. Fluconazole is well-studied and commonly used. Amphotericin B dosing is similar to adults, with careful monitoring of electrolytes and renal function.

Geriatric Considerations

Age-related declines in renal and hepatic function may alter drug clearance. Dose adjustments for fluconazole and flucytosine may be necessary based on creatinine clearance. Increased susceptibility to drug-induced QTc prolongation, nephrotoxicity, and hepatotoxicity warrants vigilant monitoring. Polypharmacy increases the risk of significant drug interactions with azoles.

Renal and Hepatic Impairment

Renal Impairment: Fluconazole requires dose reduction when creatinine clearance falls below 50 mL/min. Flucytosine dosing must be meticulously adjusted based on creatinine clearance, with therapeutic drug monitoring essential. The IV vehicle for voriconazole (cyclodextrin) accumulates in moderate-to-severe renal impairment; the oral formulation is preferred in such cases. Amphotericin B deoxycholate nephrotoxicity is exacerbated; lipid formulations are preferred. Echinocandins and itraconazole require no adjustment for renal impairment.

Hepatic Impairment: Dose reduction is recommended for voriconazole in mild-to-moderate hepatic impairment (Child-Pugh A and B); use in severe impairment is not well-defined. Ketoconazole is contraindicated. Fluconazole should be used with caution. Itraconazole is not recommended in patients with evidence of ventricular dysfunction or a history of heart failure. The metabolism of echinocandins may be reduced in hepatic impairment, but specific dosing guidelines are limited.

Summary/Key Points

• Antifungal drugs are classified by mechanism: cell membrane disruptors (polyenes), ergosterol synthesis inhibitors (azoles, allylamines), cell wall synthesis inhibitors (echinocandins), and nucleic acid synthesis inhibitors (flucytosine).
• Pharmacokinetic properties vary drastically: Fluconazole has excellent oral bioavailability and CSF penetration; voriconazole requires therapeutic drug monitoring; echinocandins and amphotericin B are IV only; azoles are potent CYP450 inhibitors with significant drug interaction potential.
• Clinical application is guided by the pathogen and host: Echinocandins are first-line for invasive candidiasis; voriconazole for aspergillosis; amphotericin B + flucytosine for cryptococcal meningitis; lipid amphotericin B for mucormycosis.
• Major toxicities are class-specific: Amphotericin B causes infusion reactions and nephrotoxicity; azoles cause hepatotoxicity, QTc prolongation, and multiple drug interactions; echinocandins are generally well-tolerated; flucytosine causes bone marrow suppression.
• Special population management is critical: Most azoles are teratogenic; amphotericin B is often used in pregnancy for life-threatening infection; dose adjustments are required in renal (fluconazole, flucytosine) and hepatic (voriconazole) impairment.

Clinical Pearls

• The combination of amphotericin B and flucytosine is synergistic against Cryptococcus and allows for lower, less toxic doses of amphotericin B.
• For voriconazole, therapeutic drug monitoring (trough target 1-5.5 μg/mL) is recommended to optimize efficacy and minimize toxicity, especially in children, patients with CYP2C19 polymorphisms, or those with changing hepatic function.
• When switching from IV to oral voriconazole, a 1:1 dose conversion can be used due to its high oral bioavailability, but levels should still be checked.
• Resistance surveillance is essential, particularly for Candida glabrata and Candida krusei, which often exhibit decreased susceptibility to fluconazole, and for emerging pathogens like Candida auris.
• For mucormycosis, prompt surgical debridement of necrotic tissue is as critical as initiating appropriate antifungal therapy (lipid formulation amphotericin B).

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.